Charles River Laboratories announced today that it has acquired SAMDI Tech, a startup founded by Milan Mrksich and spun out of our lab in 2011. SAMDI Tech uses the Self-Assembled Monolayers for MALDI Mass Spectrometry (SAMDI) technology platform developed in our lab to carry out high-throughput, label-free screening campaigns in early-stage drug discovery. The company was acquired for $50 million for the remaining 80% of the company that Charles River Labs did not already own. You can read more about the company and acquisition here.
Charles River Laboratories Acquires SAMDI Tech
